tetano
Editor, Senior Moderator
Life (Basel)
. 2022 Jan 24;12(2):168.
doi: 10.3390/life12020168.
Case Report of Cerebral Sinus Thrombosis Related to Immune Thrombotic Thrombocytopenia Following Administration of ChAdOx1 nCoV-19 for Vaccination against COVID-19
Wojciech Szypowski[SUP] 1 [/SUP], Aleksander Dębiec[SUP] 1 [/SUP], Jarosław Świstak[SUP] 1 [/SUP], Maciej Nowocień[SUP] 2 [/SUP], Piotr Rzepecki[SUP] 3 [/SUP], Marcin Możański[SUP] 4 [/SUP], Jacek Staszewski[SUP] 1 [/SUP], Adam Stępień[SUP] 1 [/SUP]
Affiliations
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST) has been recently reported after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present a case of a patient with fulminant CVST and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Although the patient received immediate anticoagulant and intravenous immune globulin treatment, he died within 24 h after hospital admission. VITT and CVST are rare conditions; however, the course may be fatal. Therefore, clinicians should be familiarized with the clinical and laboratory features of VITT.
Keywords: COVID-19; COVID-19 vaccine; CVST; VITT; thrombocytopenia.
. 2022 Jan 24;12(2):168.
doi: 10.3390/life12020168.
Case Report of Cerebral Sinus Thrombosis Related to Immune Thrombotic Thrombocytopenia Following Administration of ChAdOx1 nCoV-19 for Vaccination against COVID-19
Wojciech Szypowski[SUP] 1 [/SUP], Aleksander Dębiec[SUP] 1 [/SUP], Jarosław Świstak[SUP] 1 [/SUP], Maciej Nowocień[SUP] 2 [/SUP], Piotr Rzepecki[SUP] 3 [/SUP], Marcin Możański[SUP] 4 [/SUP], Jacek Staszewski[SUP] 1 [/SUP], Adam Stępień[SUP] 1 [/SUP]
Affiliations
- PMID: 35207456
- DOI: 10.3390/life12020168
Abstract
Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST) has been recently reported after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present a case of a patient with fulminant CVST and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Although the patient received immediate anticoagulant and intravenous immune globulin treatment, he died within 24 h after hospital admission. VITT and CVST are rare conditions; however, the course may be fatal. Therefore, clinicians should be familiarized with the clinical and laboratory features of VITT.
Keywords: COVID-19; COVID-19 vaccine; CVST; VITT; thrombocytopenia.